about
Systemic inflammation associated with World Trade Center dust exposures and airway abnormalities in the local communityElevated peripheral eosinophils are associated with new-onset and persistent wheeze and airflow obstruction in World Trade Center-exposed individualsLung pathologic findings in a local residential and working community exposed to World Trade Center dust, gas, and fumesChronic and acute exposures to the World Trade Center disaster and lower respiratory symptoms: area residents and workersCharacteristics of a residential and working community with diverse exposure to World Trade Center dust, gas, and fumesLessons from the World Trade Center disaster: airway disease presenting as restrictive dysfunctionAssociations of World Trade Center exposures with pulmonary and cardiometabolic outcomes among children seeking care for health concernsLongitudinal spirometry among patients in a treatment program for community members with World Trade Center-related illnessObstructive airways disease with air trapping among firefighters exposed to World Trade Center dustBiomarkers of World Trade Center particulate matter exposure: physiology of distal airway and blood biomarkers that predict FEV1 declineThe World Trade Center residents' respiratory health study: new-onset respiratory symptoms and pulmonary function.Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issuesUnique medical issues in adult patients with mucopolysaccharidosesIsolated small airway reactivity during bronchoprovocation as a mechanism for respiratory symptoms in WTC dust-exposed community membersImprovement in severe lower respiratory symptoms and small airway function in World Trade Center dust exposed community membersOscillometry complements spirometry in evaluation of subjects following toxic inhalationAirway dysfunction in obesity: response to voluntary restoration of end expiratory lung volumeRespiratory and sleep disorders in mucopolysaccharidosisClinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVAEnzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfataseAcute respiratory failure secondary to achalasia.Pompe disease diagnosis and management guideline.Consensus treatment recommendations for late-onset Pompe diseaseFacilitating the transition from physiology to hospital wards through an interdisciplinary case study of septic shockPulmonary Vascular Congestion: A Mechanism for Distal Lung Unit Dysfunction in Obesity.Assessing efficacy of high-frequency chest wall oscillation in patients with familial dysautonomia.Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.In search of the silver lining: the impact of Superstorm Sandy on Bellevue Hospital.Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation.Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease.Mechanism of relief of tachypnea during pressure support ventilation.Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers.Distal airway dysfunction in obese subjects corrects after bariatric surgery.Transition from acute to chronic hypercapnia in patients with periodic breathing: predictions from a computer model.Magnetic resonance imaging-based spirometry for regional assessment of pulmonary function.Progression from respiratory dysfunction to failure in late-onset Pompe disease.POINT: Should Oscillometry Be Used to Screen for Airway Disease? Yes.Rebuttal From Dr Berger et al.The role of invasive hemodynamic monitoring in an unusual case of refractory shock.Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
P50
Q23909920-30D4CE48-457B-4C2D-A306-98E3D91E8198Q23909921-7AED856F-1CB4-4752-8072-9DBCAE250F30Q23910816-6D3E5C48-BA25-4EE4-AC3B-57C9CBE11A32Q23910818-4A4A97F4-F015-40B7-9552-187D6114605FQ23915008-05D56C6A-1AA6-45CB-A53F-C4BFE44C9179Q23916084-BD018FE8-2AD3-41A9-AA65-6BA129FBF90EQ23916859-51591F50-A246-4798-B782-1E3FAEE374CEQ23918197-C4501E8B-F1E2-430B-A9D2-CCF267E6D2FEQ23918237-C18F1E4F-9E17-4CC7-99D4-02DB7A6230E7Q23918414-65548BB1-130A-48B0-8D64-8D91A1BBC25EQ24814702-B5133FAE-4C2F-45CF-9E39-D3C1F4EAC4ADQ26738901-0DB9AF9F-7C76-46C4-8389-9EB0BBF58160Q26746227-3D4ED3F4-F2F7-44B2-B01F-A30B7DBCFC45Q27908430-77F5E8BB-0A44-4EB7-8E30-DD5694D967D1Q27908433-7B83CFC7-9F1C-4994-ACC7-0A7773F484AAQ28387875-F72F348E-B9ED-4AF3-ACED-B4E5553B5ECEQ28395457-B9247D44-C139-46A0-BC70-1F04BFD876B9Q30457547-DE66A5D7-0F1A-4278-9BF6-85DFD1B182D9Q30537233-771FB8AE-57B9-48F8-A3B0-F40CDD785CFCQ33688165-64454925-14B7-4CB0-A291-09A9D641E9C3Q33811286-59395E4A-C6D8-4071-ACE7-68387D08B39CQ34567528-F370B657-57E6-42A6-B73E-E76AE8813B71Q34634354-EF36AFDE-08CD-47F1-A5EB-FF51849858C0Q35146000-5D4F0803-2BF4-485A-9115-93BC4E9F1EA6Q35976607-C1FE5909-7B49-40A8-99B8-2EFCCDD0B2C6Q36320227-8A55BE51-6D32-4AFD-A727-7AB345A182EDQ37341874-4AC473A7-4900-4DB6-AD05-61CA0263326CQ38100843-C7584AD2-DC94-453F-91B0-9212AA0669E2Q38578579-55796BE7-A23E-467C-84A2-1736CA827903Q38705673-8D60DDF3-2AAD-4CC9-8571-D5D72279CAB1Q39465858-DDB2B560-AFEA-4B5C-A411-460FA252E63CQ39635445-06439CFF-9B78-4990-811B-15F10C5DD8A2Q43798420-70E83979-F192-4E71-AFB4-BC8DBE5A2477Q46872374-E69D77E7-2CD9-4B22-8FC8-2FDC7ACCFA9AQ47712157-F4248DF9-288D-45B7-B3DD-28CB65E4A4E6Q47846950-638C21B9-C26E-4C71-B837-DC2437B31A47Q47969663-C43D03D7-CD75-4843-8641-201326827576Q47969709-4285C81F-E03C-4E73-8D9C-7FBC99F0788DQ48014780-C4DF2091-679C-418A-BD7D-AA88F480096CQ48178931-B7AF004D-B283-414E-8BB2-26828F10481A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kenneth I. Berger
@ast
Kenneth I. Berger
@en
Kenneth I. Berger
@es
Kenneth I. Berger
@nl
Kenneth I. Berger
@sl
type
label
Kenneth I. Berger
@ast
Kenneth I. Berger
@en
Kenneth I. Berger
@es
Kenneth I. Berger
@nl
Kenneth I. Berger
@sl
prefLabel
Kenneth I. Berger
@ast
Kenneth I. Berger
@en
Kenneth I. Berger
@es
Kenneth I. Berger
@nl
Kenneth I. Berger
@sl
P106
P21
P31
P496
0000-0003-4879-6071